{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:09:35Z","timestamp":1764688175212,"version":"3.46.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Changzhi People's Hospital","award":["202003"],"award-info":[{"award-number":["202003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15211-8","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:58:30Z","timestamp":1764687510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel nomogram based on DLL3 and PD-L1 for predicting the prognosis of patients with small cell lung cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaoling","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunyi","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuexiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong\u2019ai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"15211_CR1","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","DOI":"10.3322\/caac.21660"},{"issue":"34","key":"15211_CR2","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1200\/JCO.2015.63.7918","volume":"33","author":"CM Rudin","year":"2015","unstructured":"Rudin CM, Ismaila N, Hann CL, Malhotra N, Movsas B, Norris K, et al. Treatment of small-cell lung cancer: American society of clinical oncology endorsement of the American college of chest physicians guideline. J Clin Oncol. 2015;33(34):4106\u201311.","journal-title":"J Clin Oncol"},{"key":"15211_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114248","volume":"159","author":"H Zhang","year":"2023","unstructured":"Zhang H, Yang Y, Li X, Yuan X, Chu Q. Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer. Biomed Pharmacother. 2023;159:114248.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"15211_CR4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/cncr.29098","volume":"121","author":"LA Byers","year":"2015","unstructured":"Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121(5):664\u201372.","journal-title":"Cancer"},{"issue":"31","key":"15211_CR5","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","volume":"34","author":"M Reck","year":"2016","unstructured":"Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740\u20138.","journal-title":"J Clin Oncol"},{"issue":"12","key":"15211_CR6","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1200\/JCO.2016.69.4844","volume":"35","author":"M Tiseo","year":"2017","unstructured":"Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, et al. Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol. 2017;35(12):1281\u20137.","journal-title":"J Clin Oncol"},{"issue":"6","key":"15211_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39(6):619\u201330.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15211_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51\u201365.","journal-title":"Lancet Oncol"},{"issue":"12","key":"15211_CR9","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. Effect of first-line Serplulimab vs placebo added to chemotherapy on survival in patients with Extensive-Stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 2022;328(12):1223\u201332.","journal-title":"JAMA"},{"issue":"5","key":"15211_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19(5):289\u201397.","journal-title":"Nat Rev Cancer"},{"issue":"302","key":"15211_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac9459","volume":"7","author":"LR Saunders","year":"2015","unstructured":"Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A dll3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7(302):302ra136.","journal-title":"Sci Transl Med"},{"key":"15211_CR12","unstructured":"U.S.FOOD&DRAG [Internet]. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer. Accessed 21 May 2024."},{"issue":"9","key":"15211_CR13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","volume":"16","author":"F Blackhall","year":"2021","unstructured":"Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, et al. Efficacy and safety of rovalpituzumab Tesirine compared with topotecan as second-line therapy in DLL3-High SCLC: results from the phase 3 TAHOE study. J Thorac Oncol. 2021;16(9):1547\u201358.","journal-title":"J Thorac Oncol"},{"key":"15211_CR14","doi-asserted-by":"crossref","unstructured":"Johnson ML, Zvirbule Z, Laktionov K, Helland A, Cho BC, Gutierrez V, et al. Rovalpituzumab Tesirine as a maintenance therapy after First-Line Platinum-Based chemotherapy in patients with Extensive-Stage-SCLC: results from the phase 3 MERU study. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2021;16(9):1570\u201381.","DOI":"10.1016\/j.jtho.2021.03.012"},{"issue":"1","key":"15211_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-020-02004-5","volume":"18","author":"B Chen","year":"2020","unstructured":"Chen B, Li H, Liu C, Wang S, Zhang F, Zhang L, et al. Potential prognostic value of delta-like protein 3 in small cell lung cancer: a meta-analysis. World J Surg Oncol. 2020;18(1):226.","journal-title":"World J Surg Oncol"},{"key":"15211_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.lungcan.2020.07.026","volume":"147","author":"F Rojo","year":"2020","unstructured":"Rojo F, Corassa M, Mavroudis D, \u00d6z AB, Biesma B, Brcic L, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020;147:237\u201343.","journal-title":"Lung Cancer"},{"issue":"11","key":"15211_CR17","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887\u201395.","journal-title":"EMBO J"},{"key":"15211_CR18","doi-asserted-by":"crossref","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling Inhibition for cancer immunotherapy: Mechanism, Combinations, and clinical outcome. Front Pharmacol. 2017;8:561.","DOI":"10.3389\/fphar.2017.00561"},{"key":"15211_CR19","doi-asserted-by":"crossref","unstructured":"Acheampong E, Abed A, Morici M, Bowyer S, Amanuel B, Lin W, et al. Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cells. 2020;9(11).","DOI":"10.3390\/cells9112393"},{"key":"15211_CR20","doi-asserted-by":"crossref","unstructured":"Fu X, Liu Z, Xiang L, Liu M, Zheng X, Wang J, et al. PD-L1 predicts poor prognosis in surgically resected limited stage Small-Cell lung cancer. Cancer Manage Res. 2020;12:10939\u201348.","DOI":"10.2147\/CMAR.S260599"},{"issue":"11","key":"15211_CR21","doi-asserted-by":"publisher","first-page":"18021","DOI":"10.18632\/oncotarget.14935","volume":"8","author":"YL Chang","year":"2017","unstructured":"Chang YL, Yang CY, Huang YL, Wu CT, Yang PC. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. Oncotarget. 2017;8(11):18021\u201330.","journal-title":"Oncotarget"},{"issue":"9","key":"15211_CR22","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1158\/1541-7786.MCR-09-0138","volume":"7","author":"H Bougherara","year":"2009","unstructured":"Bougherara H, Subra F, Cr\u00e9pin R, Tauc P, Auclair C, Poul MA. The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. Mol Cancer Research: MCR. 2009;7(9):1525\u201333.","journal-title":"Mol Cancer Research: MCR"},{"key":"15211_CR23","unstructured":"Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y, et al. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene. 1991;6(12):2291\u20136."},{"issue":"2","key":"15211_CR24","first-page":"370","volume":"56","author":"GW Krystal","year":"1996","unstructured":"Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res. 1996;56(2):370\u20136.","journal-title":"Cancer Res"},{"key":"15211_CR25","doi-asserted-by":"crossref","unstructured":"Boldrini L, Ursino S, Gisfredi S, Faviana P, Donati V, Camacci T, et al. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Research: Official J Am Association Cancer Res. 2004;10(12 Pt 1):4101\u20138.","DOI":"10.1158\/1078-0432.CCR-03-0664"},{"issue":"11","key":"15211_CR26","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/annonc\/mdi365","volume":"16","author":"GK Dy","year":"2005","unstructured":"Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM Jr., Morton RF, et al. A phase II trial of Imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol. 2005;16(11):1811\u20136.","journal-title":"Ann Oncol"},{"key":"15211_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz264.002","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L, et al. Overall survival (OS) update in ALTER 1202: anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC). Ann Oncol. 2019. https:\/\/doi.org\/10.1093\/annonc\/mdz264.002.","journal-title":"Ann Oncol"},{"key":"15211_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109844","author":"M Binnewies","year":"2021","unstructured":"Binnewies M, Pollack JL, Rudolph J, Dash S, Abushawish M, Lee T, et al. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 2021. https:\/\/doi.org\/10.1016\/j.celrep.2021.109844.","journal-title":"Cell Rep"},{"issue":"2","key":"15211_CR29","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s00259-024-06903-7","volume":"52","author":"N Ahmadi Bidakhvidi","year":"2024","unstructured":"Ahmadi Bidakhvidi N, Gevaert T, De Schepper M, Baldewijns M, Havinga E, Deckers W, et al. Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET\/MRI in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2024;52(2):766\u201378.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"15211_CR30","doi-asserted-by":"crossref","unstructured":"Tendler S, Kanter L, Lewensohn R, Ortiz-Villal\u00f3n C, Viktorsson K, De Petris L. The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy. PLoS One. 2020;15(10):e0240973.","DOI":"10.1371\/journal.pone.0240973"},{"issue":"23","key":"15211_CR31","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","volume":"25","author":"D Morgensztern","year":"2019","unstructured":"Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, et al. Efficacy and safety of rovalpituzumab Tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res. 2019;25(23):6958\u201366.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"15211_CR32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41416-021-01356-3","volume":"125","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L, et al. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled phase 2 study. Br J Cancer. 2021;125(3):366\u201371.","journal-title":"Br J Cancer"},{"key":"15211_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042264","author":"KH Kim","year":"2022","unstructured":"Kim KH, Kim JO, Park JY, Seo MD, Park SG. Antibody-drug conjugate targeting c-Kit for the treatment of small cell lung cancer. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23042264.","journal-title":"Int J Mol Sci"},{"key":"15211_CR34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.lungcan.2017.11.018","volume":"115","author":"K Tanaka","year":"2018","unstructured":"Tanaka K, Isse K, Fujihira T, Takenoyama M, Saunders L, Bheddah S, et al. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer. 2018;115:116\u201320.","journal-title":"Lung Cancer"},{"issue":"1","key":"15211_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","volume":"18","author":"CM Rudin","year":"2017","unstructured":"Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18(1):42\u201351.","journal-title":"Lancet Oncol"},{"issue":"15suppl","key":"15211_CR36","doi-asserted-by":"publisher","first-page":"8510","DOI":"10.1200\/JCO.2021.39.15_suppl.8510","volume":"39","author":"TK Owonikoko","year":"2021","unstructured":"Owonikoko TK, Champiat S, Johnson ML, Govindan R, Izumi H, Lai WVV, et al. Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC). J Clin Oncol. 2021;39(15suppl):8510\u20138510.","journal-title":"J Clin Oncol"},{"issue":"22","key":"15211_CR37","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063\u201375.","journal-title":"N Engl J Med"},{"key":"15211_CR38","doi-asserted-by":"crossref","unstructured":"Rudin CM, Pietanza MC, Bauer TM, Spigel DR, Ready N, Morgensztern D, et al. Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).\u00a0J Clin Oncol. 2016;34(15_suppl):LBA8505-LBA.","DOI":"10.1200\/JCO.2016.34.15_suppl.LBA8505"},{"key":"15211_CR39","doi-asserted-by":"crossref","unstructured":"Schultheis AM, Scheel AH, Ozreti\u0107 L, George J, Thomas RK, Hagemann T, et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer (Oxford England: 1990). 2015;51(3):421\u20136.","DOI":"10.1016\/j.ejca.2014.12.006"},{"key":"15211_CR40","doi-asserted-by":"crossref","unstructured":"Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, Tokito T, et al. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2015;10(3):426\u201330.","DOI":"10.1097\/JTO.0000000000000414"},{"key":"15211_CR41","doi-asserted-by":"crossref","unstructured":"Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, et al. Second-line nivolumab in relapsed small-cell lung cancer: checkmate 331(\u2606). Annals Oncology: Official J Eur Soc Med Oncol. 2021;32(5):631\u201341.","DOI":"10.1016\/j.annonc.2021.01.071"},{"key":"15211_CR42","doi-asserted-by":"crossref","unstructured":"Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, et al. Nivolumab and ipilimumab as maintenance therapy in Extensive-Disease Small-Cell lung cancer: checkmate 451. J Clin Oncology: Official J Am Soc Clin Oncol. 2021;39(12):1349\u201359.","DOI":"10.1200\/JCO.20.02212"},{"key":"15211_CR43","doi-asserted-by":"crossref","unstructured":"Antonia SJ, L\u00f3pez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol. 2016;17(7):883\u201395.","DOI":"10.1016\/S1470-2045(16)30098-5"},{"key":"15211_CR44","doi-asserted-by":"crossref","unstructured":"Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH Jr., et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2020;15(4):618\u201327.","DOI":"10.1016\/j.jtho.2019.12.109"},{"key":"15211_CR45","doi-asserted-by":"crossref","unstructured":"Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Cs\u0151szi T, et al. Pembrolizumab or placebo plus Etoposide and platinum as First-Line therapy for Extensive-Stage Small-Cell lung cancer: Randomized, Double-Blind, phase III KEYNOTE-604 study. J Clin Oncology: Official J Am Soc Clin Oncol. 2020;38(21):2369\u201379.","DOI":"10.1200\/JCO.20.00793"},{"key":"15211_CR46","doi-asserted-by":"crossref","unstructured":"Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, et al. Adebrelimab or placebo plus carboplatin and Etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739\u201347.","DOI":"10.1016\/S1470-2045(22)00224-8"},{"issue":"1","key":"15211_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000374120","volume":"89","author":"JY Blay","year":"2015","unstructured":"Blay JY, Casali PG, Dei Tos AP, Le Cesne A, Reichardt P. Management of Gastrointestinal stromal tumour: current practices and visions for the future. Oncology. 2015;89(1):1\u201313.","journal-title":"Oncology"},{"issue":"8","key":"15211_CR48","first-page":"3319","volume":"6","author":"GW Krystal","year":"2000","unstructured":"Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Research: Official J Am Association Cancer Res. 2000;6(8):3319\u201326.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"15211_CR49","doi-asserted-by":"crossref","unstructured":"Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, et al. Growth Inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000;19(31):3521\u20138.","DOI":"10.1038\/sj.onc.1203698"},{"key":"15211_CR50","unstructured":"Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, et al. Phase II study of Imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003;9(16 Pt 1):5880\u20137."},{"key":"15211_CR51","doi-asserted-by":"crossref","unstructured":"Jiang M, Wu C, Zhang L, Sun C, Wang H, Xu Y, et al. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III. Journal for immunotherapy of cancer. 2021;9(5).","DOI":"10.1136\/jitc-2021-002339"},{"key":"15211_CR52","doi-asserted-by":"crossref","unstructured":"Li J, Zheng Q, Zhao X, Zhao J, An T, Wu M, et al. Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis. BMC Cancer. 2020;20(1):793.","DOI":"10.1186\/s12885-020-07271-9"},{"key":"15211_CR53","doi-asserted-by":"crossref","unstructured":"Zeng Q, Li J, Tan F, Sun N, Mao Y, Gao Y, et al. Development and validation of a nomogram prognostic model for resected Limited-Stage small cell lung cancer patients. Ann Surg Oncol. 2021;28(9):4893\u2013904.","DOI":"10.1245\/s10434-020-09552-w"},{"key":"15211_CR54","doi-asserted-by":"crossref","unstructured":"Wu LL, Chen WT, Li CW, Song SH, Xu SQ, Wan SP, et al. The Construction and Validation of Nomogram to Predict the Prognosis with Small-Cell Lung Cancer Followed Surgery. Cancers. 2022;14(15).","DOI":"10.3390\/cancers14153723"},{"key":"15211_CR55","doi-asserted-by":"crossref","unstructured":"Qi J, Zhang J, Ge X, Wang X, Xu L, Liu N, et al. The addition of peripheral blood inflammatory indexes to nomogram improves the predictive accuracy of survival in Limited-Stage small cell lung cancer patients. Front Oncol. 2021;11:713014.","DOI":"10.3389\/fonc.2021.713014"},{"key":"15211_CR56","doi-asserted-by":"crossref","unstructured":"Wei L, Hou Q, Liu J, Yao N, Liang Y, Cao X, et al. External application of a nomogram to predict survival and benefit of peripheral blood inflammatory indexes in Limited-Stage small cell lung cancer. Front Oncol. 2022;12:873367.","DOI":"10.3389\/fonc.2022.873367"},{"issue":"2","key":"15211_CR57","doi-asserted-by":"publisher","first-page":"866","DOI":"10.21037\/tlcr-20-997","volume":"10","author":"C Chen","year":"2021","unstructured":"Chen C, Yang H, Cai D, Xiang L, Fang W, Wang R. Preoperative peripheral blood neutrophil-to-lymphocyte ratios (NLR) and platelet-to-lymphocyte ratio (PLR) related nomograms predict the survival of patients with limited-stage small-cell lung cancer. Transl Lung Cancer Res. 2021;10(2):866\u201377.","journal-title":"Transl Lung Cancer Res"},{"key":"15211_CR58","doi-asserted-by":"crossref","unstructured":"Ni J, Zhang X, Wang H, Si X, Xu Y, Zhao J, et al. Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8\u2010year period. Thorac Cancer. 2021;13(4):539\u201348.","DOI":"10.1111\/1759-7714.14289"},{"key":"15211_CR59","doi-asserted-by":"crossref","unstructured":"Zhong J, Zheng Q, An T, Zhao J, Wu M, Wang Y, et al. Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis. Thorac Cancer. 2019;10(9):1788\u201397.","DOI":"10.1111\/1759-7714.13148"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15211-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15211-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15211-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:58:38Z","timestamp":1764687518000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15211-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15211"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15211-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research involving human subjects was reviewed and approved by the Medical Ethics Committee of the Changzhi People\u2019s Hospital (No.: 2020K03), in strict adherence to the principles of the Declaration of Helsinki, and informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1848"}}